Acute Migraine Treatment Market

Acute Migraine Treatment: Overview

Emergence of new drug and therapies for the acute migraine treatment is expected to account for the significant growth of the acute migraine treatment in the forecast period. Development of new drugs such as CGRP antagonists provide huge potential for the acute migraine treatment market to grow. Development of new drugs by the key pharmaceutical players such as Amgen, Novartis, Eli Lily and Company and increasing research and development funding will create huge opportunity for the market to grow in the near future. For instance, in 2017, Eli Lilly and Company’s drug for acute migraine treatment succeeded in a key late-stage study, setting the stage for regulatory approval in U.S.

Acute Migraine Treatment: Region-wise Outlook

The North America is expected to contribute to a major share in the global acute migraine treatment, due to growing prevalence of acute migraine along with the increasing funding for the development of new drug with the presence of major pharmaceutical industries. According to Migraine Research Foundation, 39 million of US population suffer from migraine and 1 billion population worldwide. 18% of women, 6% of men, and 10% of children suffers from migraines. In 2015, the medical cost of treating migraine was more than $5.4 billion, although migraine patients spent over $41 billion on treating entire range of migraine. Europe accounts for the second largest market share and register significant growth in the global acute migraine treatment market, due to increasing demand of effective treatment for the acute migraine and adoption of new therapies along with the favorable reimbursement scenarios. Asia Pacific market is primarily driven by the factors such as increasing expenditure of healthcare systems, improvement in the healthcare infrastructure and growing awareness of disease. China is expected to register significant growth in the acute migraine treatment market, due to growing population, low cost of drug and treatment, availability of drugs for the acute migraine treatment. Latin America and Middle East & Africa are projected to show sluggish growth in acute migraine treatment market, due to lack of developed healthcare facilities.

Acute Migraine Treatment: Key Players

Some of the key players present in the global acute migraine treatment market are Amgen, Pfizer Inc., Hoffmann-La Roche Ltd, Eli Lily and Company, Novartis AG, Johnson and Johnson, Merck & Co., AstraZeneca and Teva Pharmaceutical among others.

The report covers exhaustive analysis on,

• Acute Migraine Treatment Market Segments
• Acute Migraine Treatment Market Dynamics
• Historical Actual Market Size, 2012 – 2016
• Acute Migraine Treatment Market Size & Forecast 2016 to 2024
• Acute Migraine Treatment Market Current Trends/Issues/Challenges
• Competition & Companies involved
• Acute Migraine Treatment Market Drivers and Restraints

Future Market Insights is the premier provider of market intelligence and consulting services, serving client in over 160 countries. FMI is headquartered in London, the global financial capital and has delivery centers in the U.S. and India. FMI's research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure that our clients prepare for the evolving needs of their customers. FMI's team of over 200 research analysts provides market intelligence at global, regional, and country levels. Our analysts are committed to provide independent insights, relying on our cognitive training modules, which conditions them to look at data objectively and unbiasedly. Others you can use from the file Allen just shared when those will be made live.